Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma

Fig. 1

PM exhibits potent activity against MM and lymphoma cells and mouse models. a Human MM cell lines (MM1S, MM1R, RPMI-8226, RPMI-8226R, AMO1, OPM2, ARD, and KMS-11) and lymphoma cell lines (RL, Ramos, Daudi, Raji, TMD-8, SU-DHL-4, Karpas299, and NKYS) were treated with PM or panobinostat at indicated concentrations for 72 h, and cell viability were analyzed. b Primary MM and lymphoma cells from PB of MM patients (patient A and B) and lymphoma patient (patient C) were treated with PM or panobinostat at indicated concentrations, and cell apoptosis was analyzed after 48 h. c Tumor volumes and tumor weights of MM1S xenograft models treated with vehicle, PM, panobinostat, panobinostat+Bort+DXM or Len+Bort+DXM (n = 7 per group). d Kaplan-Meier survival curves for cMYC-KRAS12V PCT mice treated with vehicle, PM, panobinostat+Bort+DXM, or Len+Bort+DXM (n = 6 per group) from day 35 post-transplantation. e Cell viability of ascites cells from cMYC-KRAS12V mice after treated with PM or panobinostat in vitro (n = 3 per group). f, g Tumor volumes and tumor weights of DEL and r/r DLBCL PDX mouse models treated with vehicle, PM, R-CHOP, or Pola-BR (n = 6 per group in DEL PDX, n = 5 per group in r/r DLBCL PDX). All data are represented as mean ± SEM (standard error of the mean). ns P > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, compared with the specified group

Back to article page